KMPH - KemPharm, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3200
-0.1900 (-7.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.5100
Open2.4900
Bid2.15 x 900
Ask2.75 x 1200
Day's Range2.2700 - 2.4900
52 Week Range2.0010 - 8.4000
Volume204,885
Avg. Volume331,452
Market Cap61.377M
Beta (3Y Monthly)2.86
PE Ratio (TTM)N/A
EPS (TTM)-4.07
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.58
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research assessing the intravenous (IV) abuse potential of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), will be presented by Megan Shram, Ph.D., at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP). SDX is the major active pharmaceutical ingredient in KP415 and KP484, KemPharm’s co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder (ADHD), as well as KP879, a newly developed product candidate designed for the treatment of Stimulant Use Disorder (SUD).

  • PR Newswire5 days ago

    KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

    CELEBRATION, Fla., Dec. 11, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., presented at an interactive online investor conference. KemPharm's presentation will be available for 90 days.  In addition, investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

  • PR Newswire12 days ago

    Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire13 days ago

    KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

    CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.

  • What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
    Simply Wall St.20 days ago

    What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?

    A look at the shareholders of KemPharm Inc (NASDAQ:KMPH) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...

  • GlobeNewswire25 days ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 KemPharm Inc Earnings Call

  • GlobeNewswirelast month

    KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the addition of a new product candidate, KP879, which the company plans to develop as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD). Based on current timelines, KemPharm expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for KP879 as early as the end of 2018.

  • GlobeNewswirelast month

    KemPharm, Inc. Reports Third Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01.

  • GlobeNewswirelast month

    KemPharm to Report Third Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2018 -- KemPharm, Inc..

  • GlobeNewswire2 months ago

    KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs today announced its entry into a definitive collaboration and license agreement with KVK Tech, Inc. for the U.S. commercial rights of its FDA-approved prodrug product, APADAZ (benzhydrocodone and acetaminophen tablets). Under the terms of the agreement, KemPharm is eligible to receive up to an estimated $3.4 million in pre-launch payments and certain cost reimbursements, including a $2.0 million payment upon achievement of a specified milestone related to the initial formulary adoption of APADAZ, as well as an aggregate of up to $53 million in milestone payments tied to specific net sales levels.  In addition, net profits will be shared between KemPharm and KVK up to 50% based on achieving specified net sales levels.

  • GlobeNewswire2 months ago

    KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

    CORALVILLE, Iowa, Oct. 24, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today.

  • GlobeNewswire2 months ago

    KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

    Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LATTM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018.

  • GlobeNewswire2 months ago

    KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

    Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and.

  • MarketWatch2 months ago

    Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings

    Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq's decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that priced at deep discounts. KemPharm offered 8.33 million shares, representing 52% of the shares outstanding, that priced at $3.00 a share, or 28% below Thursday's closing price of $4.18. Meanwhile, Aytu offered 457,007 shares of common stock, 8.34 million shares of preferred stock convertible into 8.34 million shares of common stock at a conversion price of $1.50 per share, and warrants to buy and additional 8 million shares of common stock at an exercise price of $1.50 a share. That price was 26% below Thursday's closing price of $2.02. Aytu had 1.80 million shares outstanding as of Aug. 31. KemPharm shares have now lost 56% over the past three months and Aytu's stock has dropped 75%, while the S&P 500 has gained 6.1%.

  • GlobeNewswire2 months ago

    KemPharm Announces Proposed Public Offering of Common Stock

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by KemPharm.  In addition, KemPharm intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

  • GlobeNewswire2 months ago

    KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

    Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET CORALVILLE, Iowa, Oct. 03, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company.

  • Zacks3 months ago

    KemPharm Posts Positive Top-Line Results on KP415 Prodrug

    KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.